Resources

Chris Molloy Q2 2026 finance report, investment in Draig Therapeutics, MHRA meeting, centure capital summit and upcoming BIA events

How to unlock the UK's innovative life sciences and biotech potential

Jane Wall discusses investment in Alchemab Therapeutics, Life Sciences Sector Plan: one year on, regulatory and trade links, Women in Biotech and BIA members lounge

Discover how BIA members influenced the UK Life Sciences Sector Jobs Plan, addressing critical biotech talent shortages, lab skills and AI innovation

Chris Molloy on scale-up policy, improving treatments pipeline, LSSP, GMM regulation, LLSW, MDUK's Pedal Paddle Peak and Dr Sally Ann Forsyth OBE

The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.

BIO 2026, UK-China relations, EU biosolutions, TechBio X, expanding overseas and BIA Summer Party

New AI infrastructure, the MHRA AI Sandbox, life science leadership, global advocacy and BIA’s upcoming events

The challenge of converting scientific progress into real-world access

Chris Molloy on building on Parliament Day's momentum, TechBio's breakthrough week, the Oxford-to-Cambridge expansion, and driving global investor confidence at the Leadership Summit

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

BIA members gathered in London on Tuesday for our 26th annual Parliament Day

Chris Molloy on Parliament Day, the EU start-up fund, MHRA rare disease regulation, Northern Ireland, women in biotech and scientific leadership

Chris Molloy discusses Government engagement, the King’s Speech, health data, Isomorphic’s huge raise, the Start-up Festival and expanding BIA’s reach

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament

In this guest blog, Asma Aslam says that rising domestic costs and strong overseas capabilities are pushing companies to subcontract abroad.

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.